BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37222147)

  • 1. Profiling of pharmacogenomic variants in
    Alsulaiman A; Chu H; Al-Jumaan M; Alyahya M; Marzooq YA; Almulhim F; Vatte C; Alnimer A; Almuhanna A; Al-Ali A; AlDubayan SH
    Pharmacogenomics; 2023 May; 24(7):411-423. PubMed ID: 37222147
    [No Abstract]   [Full Text] [Related]  

  • 2. Frequency of pharmacogenomic variants affecting efficacy and safety of anti-cancer drugs in a south Asian population from Sri Lanka.
    Ranasinghe P; Sirisena N; Vishnukanthan T; Ariadurai JN; Thilakarathne S; Priyadarshani CDN; Bhagya Hendalage DP; Dissanayake VHW
    BMC Med Genomics; 2024 May; 17(1):143. PubMed ID: 38789983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of CYP2D6*10 (c. 100 C>T) Genotype with Z-END Concentration in Patients with Breast Cancer Receiving Tamoxifen Therapy in Indonesian Population.
    Yenny ; Panigoro SS; Purwanto DJ; Hidayat A; Louisa M; Andalusia R; Setiabudy R
    Endocr Metab Immune Disord Drug Targets; 2019; 19(8):1198-1206. PubMed ID: 30843495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen.
    Abraham JE; Maranian MJ; Driver KE; Platte R; Kalmyrzaev B; Baynes C; Luccarini C; Shah M; Ingle S; Greenberg D; Earl HM; Dunning AM; Pharoah PD; Caldas C
    Breast Cancer Res; 2010; 12(4):R64. PubMed ID: 20731819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomics toward personalized tamoxifen therapy for breast cancer.
    Zembutsu H
    Pharmacogenomics; 2015; 16(3):287-96. PubMed ID: 25712191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
    Punglia RS; Burstein HJ; Winer EP; Weeks JC
    J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer.
    Nardin JM; Schroth W; Almeida TA; Mürdter T; Picolotto S; Vendramini ECL; Hoppe R; Kogin JP; Miqueleto D; de Moraes SDR; Schwab M; Pecoits-Filho RF; Brauch H; Casali-da-Rocha JC
    Clin Transl Sci; 2020 Mar; 13(2):284-292. PubMed ID: 31573754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.
    Helland T; Henne N; Bifulco E; Naume B; Borgen E; Kristensen VN; Kvaløy JT; Lash TL; Alnæs GIG; van Schaik RH; Janssen EAM; Hustad S; Lien EA; Mellgren G; Søiland H
    Breast Cancer Res; 2017 Nov; 19(1):125. PubMed ID: 29183390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population.
    Lan B; Ma F; Zhai X; Li Q; Chen S; Wang J; Fan Y; Luo Y; Cai R; Yuan P; Zhang P; Li Q; Xu B
    Int J Cancer; 2018 Jul; 143(1):184-189. PubMed ID: 29396856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen.
    Chan CWH; Law BMH; So WKW; Chow KM; Waye MMY
    J Cancer Res Clin Oncol; 2020 Jun; 146(6):1395-1404. PubMed ID: 32270286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study.
    Sanchez-Spitman A; Dezentjé V; Swen J; Moes DJAR; Böhringer S; Batman E; van Druten E; Smorenburg C; van Bochove A; Zeillemaker A; Jongen L; Los M; Neven P; Gelderblom H; Guchelaar HJ
    J Clin Oncol; 2019 Mar; 37(8):636-646. PubMed ID: 30676859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2D6 and tamoxifen: DNA matters in breast cancer.
    Hoskins JM; Carey LA; McLeod HL
    Nat Rev Cancer; 2009 Aug; 9(8):576-86. PubMed ID: 19629072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
    Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN
    Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Underrated Risks of Tamoxifen Drug Interactions.
    Hansten PD
    Eur J Drug Metab Pharmacokinet; 2018 Oct; 43(5):495-508. PubMed ID: 29637493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2D6 Genotype and Risk of Recurrence in Tamoxifen Treated Breast Cancer Patients.
    Yazdi MF; Rafieian S; Gholi-Nataj M; Sheikhha MH; Nazari T; Neamatzadeh H
    Asian Pac J Cancer Prev; 2015; 16(15):6783-7. PubMed ID: 26434912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy.
    Thompson AM; Johnson A; Quinlan P; Hillman G; Fontecha M; Bray SE; Purdie CA; Jordan LB; Ferraldeschi R; Latif A; Hadfield KD; Clarke RB; Ashcroft L; Evans DG; Howell A; Nikoloff M; Lawrence J; Newman WG
    Breast Cancer Res Treat; 2011 Jan; 125(1):279-87. PubMed ID: 20809362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2D6 Genetic Polymorphisms and Phenotypes in Different Ethnicities of Malaysian Breast Cancer Patients.
    Chin FW; Chan SC; Abdul Rahman S; Noor Akmal S; Rosli R
    Breast J; 2016; 22(1):54-62. PubMed ID: 26510986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional characterization of 22 novel CYP2D6 variants for the metabolism of Tamoxifen.
    Hu XX; Zhou Q; Lan T; Huang XX; Liang BQ; Dai DP; Cai JP; Hu GX
    J Pharm Pharmacol; 2016 Jun; 68(6):819-25. PubMed ID: 27109434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National Prociency Testing Result of CYP2D6*10 Genotyping for Adjuvant Tamoxifen Therapy in China.
    Lin G; Zhang K; Yi L; Han Y; Xie J; Li J
    PLoS One; 2016; 11(9):e0162361. PubMed ID: 27603206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomics, CYP2D6, and Tamoxifen: A Survey of the Reasons Sustaining European Clinical Practice Paradigms.
    Reis SS; Carvalho AS; Fernandes R
    Medicina (Kaunas); 2019 Jul; 55(7):. PubMed ID: 31284530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.